ArticleMethods in molecular biology (Clifton, N.J.)2025
SUMO Antibody Validation.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tools to detect endogenous SUMOylation are critical for capturing and analyzing SUMOylation dynamics. Proteome-wide analysis of SUMOylation has provided invaluable insight into our understanding of global patterns of SUMOylation under various developmental and stressor conditions. Experimental validation of SUMOylation is still essential for a detailed mechanistic understanding of SUMOylation of individual proteins. In most cases, antibodies raised to SUMO are the tools of choice. Several high-quality monoclonals and their hybridomas (8A2 to SUMO2/3, 21C7 and 76-86 for SUMO1) have been made widely available to the research community (Becker et al., Nat Struct Mol Biol 20:525-531, 2013). These tools are helpful in identifying individual substrates and as affinity reagents for global proteomic SUMOylome profiling. In addition to these tools, many SUMO1-4 antibodies are commercially available, including almost 100 monoclonal antibodies (MAbs). In testing 24 SUMO1-4 MAbs across multiple detection formats (Garvin et al., Sci Rep:12, 2022), we uncovered several poorly specific published MAbs, including SUMO4 MAbs, that robustly cross-react with SUMO2/3 and vice versa. Inconsistencies between different SUMO MAbs were prevalent in their ability to detect monomeric, conjugated, and polymeric forms of SUMO. The ability to detect changes in SUMOylation across stress conditions also varied widely between SUMO MAbs. As each SUMO MAb tested had strengths and weaknesses, researchers must be aware of these caveats when selecting antibodies for their research needs. This chapter provides protocols for validating SUMO antibodies. As many vendors provide little experimental validation for their antibodies, these validations are critical to prevent wasting precious time and resources for researchers. The proper validation of antibodies is also increasingly a prerequisite for research funding agencies, publishing, and promoting reproducibility in research.
Indexed as
Identifiers
40875112What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.